Phage Therapy

Phase 2Biologic

AAdaptive Phage Therapeutics, Inc.

Phage Therapy is one of 84 biologic programs targeting Periprosthetic Joint Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Periprosthetic Joint InfectionNot yet recruiting

Prosthetic-Joint InfectionWithdrawn

Urinary Tract InfectionActive, not recruiting

Spinal Cord InjuryRecruiting

Periprosthetic Joint InfectionPhase 2

Not yet recruiting

Prosthetic-Joint InfectionPhase 2

Withdrawn

Urinary Tract InfectionPhase 2

Active, not recruiting

Spinal Cord InjuryPhase 1

Recruiting

Competition

Competitive Landscape

62 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

5 2

Keppra

UCB

Approved

1 3

Cialis

Eli Lilly

Approved

1 4

Ozempic

Novo Nordisk

Approved

1 5

Elavil

AstraZeneca

Approved

1 6

Levitra

Bayer

Approved

1 7

Lioresal

Calciferol

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 10

Prolia

OOrganon and Co

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Spinal Cord Injury

NCT06559618

Q1 2027

Phase 1/2Recruiting

Kidney Transplant

NCT06409819

Clinical

Trials by Indication[1]

Prosthetic-joint Infection4 trials

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

Withdrawn·AAdaptive Phage Therapeutics, Inc.·Phase 1/2·NCT04787250

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Withdrawn·AAdaptive Phage Therapeutics, Inc.·Phase 1/2·NCT05269121

Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection

Active, not recruiting·UUniversity of Calgary·Phase 1/2·NCT06814756·1 enrolled

Show 1 more trial

Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection

Active, not recruiting·UUniversity of Calgary·Phase 1/2·NCT06456424·1 enrolled

Urinary Tract Infection1 trial

Phage Therapy for the Treatment of Urinary Tract Infection

Active, not recruiting·UUnity Health Toronto·Phase 1/2·NCT05537519·1 enrolled

Kidney Transplant1 trial

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

Recruiting·UUniversity of California, San Diego·Phase 1/2·NCT06409819·32 enrolled

Periprosthetic Joint Infection1 trial

Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection

Not yet recruiting·OOrthopaedic Innovation Centre·Phase 1/2·NCT06942624·1 enrolled

Spinal Cord Injury1 trial

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

Recruiting·BBarbara Wells Trautner·Phase 1·NCT06559618·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Phage Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phage Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phage Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adaptive Phage Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAdaptive Phage Therapeutics, Inc.

Phage Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Prosthetic-joint Infection4 trials

Urinary Tract Infection1 trial

Kidney Transplant1 trial

Periprosthetic Joint Infection1 trial

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News